share_log

Aurora Cannabis | 6-K: Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration

Aurora Cannabis | 6-K: Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration

極光大麻 | 6-K:極光大麻和Vectura Fertin製藥公司宣佈商業合作
美股SEC公告 ·  2024/08/07 02:27

Moomoo AI 已提取核心訊息

Aurora Cannabis and Vectura Fertin Pharma announced a commercial collaboration on August 1, 2024. The partnership will initially launch Cogent International's new CBD lozenge on Aurora's Canadian medical cannabis patient platform. This collaboration aims to gather patient feedback and build real-world data for future analysis.Following a successful launch, the companies may explore opportunities to commercialize other Vectura Fertin Pharma medical cannabis products in Canada. The agreement has an initial term of 24 months, with the first SKU targeted for launch later in 2024. Cogent will manufacture, package, and label the products for sale and distribution through Aurora's e-commerce channel.This partnership leverages Aurora's leading patient platform in Canada to support advancements in medical cannabis and provide patients access to new products. It also demonstrates increased interest in medical cannabis as a healthcare option for Canadians, aligning with both companies' focus on improving people's lives through scientific innovation and high-quality products.
Aurora Cannabis and Vectura Fertin Pharma announced a commercial collaboration on August 1, 2024. The partnership will initially launch Cogent International's new CBD lozenge on Aurora's Canadian medical cannabis patient platform. This collaboration aims to gather patient feedback and build real-world data for future analysis.Following a successful launch, the companies may explore opportunities to commercialize other Vectura Fertin Pharma medical cannabis products in Canada. The agreement has an initial term of 24 months, with the first SKU targeted for launch later in 2024. Cogent will manufacture, package, and label the products for sale and distribution through Aurora's e-commerce channel.This partnership leverages Aurora's leading patient platform in Canada to support advancements in medical cannabis and provide patients access to new products. It also demonstrates increased interest in medical cannabis as a healthcare option for Canadians, aligning with both companies' focus on improving people's lives through scientific innovation and high-quality products.
極光大麻與Vectura Fertin Pharma於2024年8月1日宣佈了一項商業合作。該合作關係將最初在極光的加拿大醫療大麻患者平台上推出Cogent International的新型CBD含片。此合作旨在收集患者反饋,併爲未來的分析建立真實世界的數據。在成功推出後,公司可能會探索在加拿大商業化其他Vectura Fertin Pharma醫療大麻產品的機會。該協議的初始期限爲24個月,首個SKU預計將在2024年晚些時候推出。Cogent將負責製造、包裝和標籤產品,並通過極光的電子商務渠道進行銷售和分銷。該合作利用了極光在加拿大領先的患者平台,以支持醫療大麻的進展,併爲患者提供新產品的訪問。這也表明了加拿大人對醫療大麻作爲醫療選擇的興趣增加,與兩家公司通過科學創新和高質量產品改善人們生活的目標一致。
極光大麻與Vectura Fertin Pharma於2024年8月1日宣佈了一項商業合作。該合作關係將最初在極光的加拿大醫療大麻患者平台上推出Cogent International的新型CBD含片。此合作旨在收集患者反饋,併爲未來的分析建立真實世界的數據。在成功推出後,公司可能會探索在加拿大商業化其他Vectura Fertin Pharma醫療大麻產品的機會。該協議的初始期限爲24個月,首個SKU預計將在2024年晚些時候推出。Cogent將負責製造、包裝和標籤產品,並通過極光的電子商務渠道進行銷售和分銷。該合作利用了極光在加拿大領先的患者平台,以支持醫療大麻的進展,併爲患者提供新產品的訪問。這也表明了加拿大人對醫療大麻作爲醫療選擇的興趣增加,與兩家公司通過科學創新和高質量產品改善人們生活的目標一致。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息